quarter fine albeit puts-and-tak howev anoth cyno
reset put manag deeper penalti box forc us reduc
fundament long-term outlook growth interestingli chang
neg impact view outlook valuat multipl ep
maintain rate reduc p-t
first good news report revenu ahead consensu
organ growth exclud blood screen cynosur line
expect might exceed expect neg impact
flu weather volum within core would also note breast health
sale continu hold better expect myosur perform
solid bad news cynosur sale came light
expect pretti low quarter novasur sale
continu struggl
combin revenu upsid gross margin come light
expect oper spend come expect higher revenu base drove
oper margin puts-and-tak bottom line ep
y/i line expect y/i declin gross margin driven
unfavor product geograph mix share count lower
forecast off-set higher expect non-oper expens
full year revenu guidanc cut decreas
midpoint full year constant currenc growth guidanc cut
decreas midpoint primari driver cc growth
guidanc reduct cynosur estim full year cynosur guidanc reduc
previous forecast bit
prior guidanc notabl full year ep guidanc reiter despit
lower revenu expect manag scale back opex invest
seemingli increasingli focus control cost revenu ep guid
prior consensu prior consensu
guidanc impli target cynosur revenu translat
sequenti growth vs keep mind typic season stronger
cynosur quarter sale forc turnov appear stabil reluctantli
assert target seem reason
continu page
pleas see page report import disclosur
believ posit sustain core revenu growth next
sever year even cynosur grow combin
margin expans opportun capit deploy drive ep growth
discount peer yield risk/reward favor
tax rate trend downward remain
us tax reform drive tax rate low
high
cynosur growth return
ep growth
cynosur outperform expect
ep growth
return growth
ep growth
develop manufactur supplier premium diagnost medic imag
system surgic product dedic healthcar need women compani
core busi segment focus breast health diagnost gyn surgic
skelet health august acquir gen-prob global leader
develop manufactur market rapid accur cost-effect molecular
diagnost product servic use primarili diagnos human diseas
key pillar decemb upgrad thesi link would build
confid outlook msd core revenu growth relat outlook dd
ep growth combin thing would result multipl expans
peer group level point fair say strongli lack confid pillar
first pillar thesi depend manag stabil cynosur
return growth time albeit never level consist origin manag
target key core growth area surgic sale maintain
reason momentum consist origin guidanc key core area
concern breast health pap test hold better mani fear
molecular diagnost grow street expect remain confid
 believ wrong base recent updat novasur
perform anoth exampl poor execut year
forecast core revenu growth includ
assumpt cynosur grow corpor averag could prove
conserv post-deal execut suggest time get pretti meter
expect good news still strong convict outlook core
growth via hsd high-margin mdx revenu growth lsd growth core
busi concern breast health ww pap msd-hsd surgic growth even
novasur pressur
combin benefici mix meter oper invest plan support
view ep estim need reduc materi due revenu cut
fact cut ep estim correspond
import note balanc sheet also clear dilut convert debt
gener enough annual support annual ep growth via
past year typic trade premium
translat ep note would also translat
discount peer open level indic aftermarket
would valu discount peer respect
despit numer recent challeng appear track maintain
oper margin among best class fcf/ni convers rate dcf
basi get valuat assum margin remain long-
term perpetu revenu growth exceed assumpt appear
adequ prudent us reduc price target base mix
line price-to-earnings multipl dcf analysi
compani report thomson eikon cowen compani
cowen vs consensu mm except cc msd organ fx cc gross expect expans base increment d/sg spend due tax save ep revenu metric mm except statement mm except per count consensu breast revenu consensu forecast cc revenu growth forecast beat larg driven breast imag notabl ou breast revenu grew third consecut quarter growth ou busi manag note newer system see good adopt addit ancillari product includ services/softwar help off-set matur placement us streetaccount consensu skelet revenu consensu forecast growth driven dxa product servic streetaccount consensu surgic revenu light consensu light forecast importantli myosur revenu increas y/i forecast novasur key driver miss rel forecast novasur revenu quarter declin y/i encouragingli manag note order pattern continu support improv trend revenu report excl blood/cynosur exceed consensu forecast report basi segment surgic cynosur met/exceed expect howev organ growth exclud blood screening/cynosur light forecast primarili due diagnost larg due flu/weath novasur exclud impact flu/weath estim core growth would least line forecast gross margin declin y/i expect manag note declin due unfavor mix ous/cynosur sale lower gross margin divest blood screen busi higher gross margin expens forecast appear manag scale back spend light unfavor mix cynosur weak sg expens forecast oper margin declin y/i light expect similar gross margin perform y/i declin driven unfavor product geograph mix streetaccount consensu diagnost revenu consensu forecast diagnost organ revenu growth exclud blood screen forecast larg driven lower expect mdx revenu manag attribut weaker expect mdx revenu flu/incl weather quarter base channel check market assess continu believ mdx busi sustain hsd grower streetaccount consensu cynosur revenu consensu ahead forecast importantli full fiscal year cynosur revenu expect materi cut estim guidanc due continu sale forc rate line forecast ep y/i line expect share count lower forecast off-set higher expect non-oper expens cowen
compani report thomson eikon cowen compani
cagrcommentstot cc fx lsd organ msd organ cynosur key driver chang msd growth excl blood re-affirmed molecular like contribut annual mdx revenueblood blood us mixbreast growth like better initi lsd guidancebreast imag incl breast lsd growth revenu sequenti revenu sequenti higher full year materi excl blood royalti grth excl blood breast normal deal excl blood royalti grth excl blood breast excl blood royalti cyno inorgan grth excl blood grth excl blood cowen
compani report thomson eikon cowen compani
except per share cc fx lsd organ msd organ cynosur key driver chang organ cc fx expect expans base blood screen headwind fy gross scale back plan d/sg spend gener scale back plan d/sg spend oper scale back plan d/sg spend non-oper interest net non-oper expens materi higher y/yearn tax rate reiter net earn per ep reiter share count except per share gross op consensu cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit cynosur much wors
current model headwind growth novasur pap test
reform stall dc enter agreement larg refer
laboratori maintain busi import mdx franchis
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
